Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | TP53 | P04637 | 1/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | SLC29A1 | Q99808 | 6/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.71 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.71 |
| ▸ | NT5E | P21589 | 2/20 | 0.68 |
| ▸ | PGK1 | P00558 | 1/20 | 0.68 |
| ▸ | PGK2 | P07205 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7100664 | 1.00 | LMNA (0.78) | LMNATP53CYP2C19SLC29A1ADORA3 | |
| SCHEMBL30495908 | 1.00 | LMNA (0.78) | LMNATP53CYP2C19SLC29A1ADORA3 | |
| SCHEMBL637421 | 1.00 | LMNA (0.78) | LMNATP53CYP2C19SLC29A1ADORA3 | |
| SCHEMBL12987511 | 1.00 | LMNA (0.78) | LMNATP53CYP2C19SLC29A1ADORA3 | |
| SCHEMBL637420 | 1.00 | LMNA (0.78) | LMNATP53CYP2C19SLC29A1ADORA3 | |
| SCHEMBL18464460 | 1.00 | LMNA (0.78) | LMNATP53CYP2C19SLC29A1ADORA3 | |
| SCHEMBL23680013 | 1.00 | LMNA (0.78) | LMNATP53CYP2C19SLC29A1ADORA3 | |
| SCHEMBL14163069 | 1.00 | LMNA (0.78) | LMNATP53CYP2C19SLC29A1ADORA3 | |
| SCHEMBL14853642 | 1.00 | LMNA (0.78) | LMNATP53CYP2C19SLC29A1ADORA3 | |
| SCHEMBL18844791 | 1.00 | LMNA (0.78) | LMNATP53CYP2C19SLC29A1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023156601-A1 | DIAGNOSTICS FOR DETECTING ECTO-5'-NUCLEOTIDASE (CD73) | Westfälische Wilhelms-Universität Münster (DE) | 2023-08-24 | — | — | WO | disclosed |
| EP-3505176-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | Moderna Therapeutics, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| US-9878056-B2 | Modified polynucleotides for the production of cosmetic proteins and peptides | MODERNATX, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9827332-B2 | Modified polynucleotides for the production of proteins | MODERNATX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828416-B2 | Modified polynucleotides for the production of secreted proteins | MODERNATX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9790531-B2 | Enzymes and polymerases for the synthesis of RNA | MODERNATX, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9782462-B2 | Modified polynucleotides for the production of proteins associated with human disease | MODERNATX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170130255-A1 | ENZYMES AND POLYMERASES FOR THE SYNTHESIS OF RNA | MODERNATX, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX, INC. | 2017-03-02 | — | — | US | disclosed |
| US-9572897-B2 | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins | MODERNATX, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20140179771-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING DOLICHYL-PHOSPHATE (UDP-N-ACETYLGLUCOSAMINE) N-ACETYLGLUCOSAMINEPHOSPHOTRANSFERASE 1 (GLCNAC-1-P TRANSFERASE) PROTEIN DEFICIENCY | MODERNA THERAPEUTICS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140171485-A1 | MODIFIED POLYNUCLEOTIDES ENCODING CD28 MOLECULE | MODERNA THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140155473-A1 | MODIFIED GLUCOSIDASE, BETA, ACID POLYNUCLEOTIDES FOR TREATING PROTEIN DEFICIENCY | Moderna Threrapeutics, Inc. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140141067-A1 | MODIFIED POLYNUCLEOTIDES ENCODING SEPTIN-4 | MODERNA THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140010861-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | modeRNA Therapeutics (US) | 2014-01-09 | — | — | US | disclosed |
| US-20130237594-A1 | SPLIT DOSE ADMINISTRATION | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | modeRNA Therapeutics (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130156849-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | modeRNA Therapeutics (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140141067-A1 | MODIFIED POLYNUCLEOTIDES ENCODING SEPTIN-4 | SEPTIN7, SEPTIN9, SEPTIN8 | LMNA 673/4885TP53 168/4885CYP2C19 4657/4885 |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | LMNA 585/4885TP53 836/4885CYP2C19 4275/4885 |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | LMNA 585/4885TP53 836/4885CYP2C19 4275/4885 |
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | RNGTT, L3MBTL3, RNASE1 | LMNA 281/4885TP53 782/4885CYP2C19 4779/4885 |
| US-20130237594-A1 | SPLIT DOSE ADMINISTRATION | IGF2BP1, IGF2BP2, NSUN2 | LMNA 292/4885TP53 54/4885CYP2C19 4853/4885 |
| US-20130156849-A1 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS | NSUN2, RNMT, NSUN3 | LMNA 122/4885TP53 164/4885CYP2C19 4841/4885 |
| US-20140179771-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING DOLICHYL-PHOSPHATE (UDP-N-ACETYLGLUCOSAMINE) N-ACETYLGLUCOSAMINEPHOSPHOTRANSFERASE 1 (GLCNAC-1-P TRANSFERASE) PROTEIN DEFICIENCY | POLRMT, POLN, GALNT1 | LMNA 537/4885TP53 2288/4885CYP2C19 4759/4885 |
| US-20140010861-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | POLRMT, POLM, POLN | LMNA 234/4885TP53 576/4885CYP2C19 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.